Simultaneous determination of primary volatile components in Tibetan medicine Bawei Chenxiang powders by GC

Published on Nov. 18, 2024Total Views: 734 times Total Downloads: 127 times Download Mobile

Author: SU Meiyun ^1, ^2, ³ WANG Pei ^1, ^2, ³ LIU Yanping ^2, ³  XIE Hebing ^1, ^2, ^3, ⁴ BAIMA Danzeng ^3, ⁴

Affiliation: 1. School of Pharmacy, Anhui University of Traditional Chinese Medicine, Hefei 230012, China 2. Nantong Haimen Yangtze Delta Drug Advanced Research Institute, Nantong 226133, Jiangsu Province, China 3. Jiangsu Shenhou Pharmaceutical Research Co., Ltd, Nantong 226133, Jiangsu Province, China 4. Tibet Shenhou Pharmaceutical Co., Ltd, Shigatse 857000, Xizang Autonomous Region,China

Keywords: Bawei Chenxiang powders Volatile components Octyl acetate Benzylacetone Myristicin Dehydrocostus lactone Gas chromatography Content determination

DOI: 10.12173/j.issn.1005-0698.202403035

Reference: SU Meiyun, WANG Pei, LIU Yanping, XIE Hebing, BAIMA Danzeng.Simultaneous determination of primary volatile components in Tibetan medicine Bawei Chenxiang powders by GC[J].Yaowu Liuxingbingxue Zazhi,2024, 33(11):1247-1253.DOI: 10.12173/j.issn.1005-0698.202403035.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To establish a GC method for simultaneous determination of volatile index components of octyl acetate, benzylacetone, myristicin and dehydrocostus lactone in Tibetan medicine Bawei Chenxiang powders.

Methods A GC method was used with octyl acetate, benzylacetone, myristicin and dehydrocostus lactone as indicator components, SH-WAX capillary column (30 m×0.25 mm, 0.25 µm) and temperature programming were used, the carrier gas was nitrogen, the inlet temperature was 220 ℃, the detector temperature was 240 ℃, with split injection volume of 1 µL.

Results The concentrations of octyl acetate, benzylacetone, myristicin and dehydrocostus lactone showed a good linear relationship with peak area (r≥0.999 5) in the range of 12.44-124.43 μg·mL^-1, 2.90-29.01 μg·mL^-1, 15.95-159.45 μg·mL^-1, 15.62-156.15 μg·mL^-1, respectively; the average recovery rates were 100.40% (RSD=1.55%), 97.80% (RSD=1.41%), 99.50% (RSD=0.77%) and 99.50% (RSD=0.85%) (n=6).

Conclusion The method has good specificity, precision, repeatability and accuracy, and can be used for the determination of volatile index components in Bawei Chenxiang powders.

Full-text

Please download the PDF version to read the full text: download

References

1.中华人民共和国卫生部药品标准·藏药第一册[S]. 1992: 4.

2.中国药典2020年版. 一部[S]. 2020: 481.

3.王倩, 杨建鑫, 刘贵琴, 等. 藏药治疗脑缺血疾病的研究进展[J]. 药学研究, 2021, 40(2): 97-102, 109. [Wang Q, Yang JX, Liu GQ, et al. Research progress of Tibetan medicine on cerebral ischemic diseases[J]. Journal of Pharmaceutical Research, 2021, 40(2): 97-102, 109.] DOI: 10.13506/j.cnki.jpr.2021.02.008.

4.马春秀, 李彩霞, 宫佰会, 等. 藏药八味沉香散血清对H9c2心肌细胞缺氧/复氧损伤的保护作用[J]. 中国高原医学与生物学杂志, 2022, 43(2): 121-126. [Ma CX, Li CX, Gong BH, et al. Protective effects of serum of Tibetan medicine Bawei Chenxiang Powder on the hypoxia/reoxygenation injury of H9c2 myocardial cells[J]. Chinese High Altitude Medicine and Biology, 2022, 43(2): 121-126.] DOI: 10.13452/j.cnki.jqmc.2022.02.007.

5.李永慧, 朱琳, 寇毅英, 等. 八味沉香散对大鼠心肌缺血再灌注损伤的保护作用[J]. 中成药, 2022, 44(9): 3027-3030. DOI: 10.3969/j.issn.1001-1528.2022.09.053.

6.朱琳, 李永芳, 李向阳. 藏药八味沉香散的有效成分及药理作用研究进展[J]. 中国民族民间医药, 2019, 28(14): 73-76. [Zhu L, Li YF, Li XY. Advances in the analysis of active ingredients and pharmacological effects of Tibetan medicine Bawei Chenxiang Powder[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2019, 28(14): 73-76.] DOI: CNKI:SUN:MZMJ.0.2019-14-020.

7.王佳铭, 曹境洳, 高小力, 等. 八味沉香散的化学和药理研究进展[J]. 中国中药杂志, 2020, 45(9): 2063-2072. [Wang JM, Cao JR, Gao XL, et al. Chemical and pharmacological progress on a Tibetan folk medicine formula Bawei Chenxiang powders[J]. China Journal of Chinese Materia Medica, 2020, 45(9): 2063-2072.] DOI: 10.19540/j.cnki.cjcmm.20200224.201.

8.白发平, 靳若宁, 唐硕, 等. 中药沉香化学成分、药理作用及其应用研究进展[J]. 中国野生植物资源, 2022, 41(12): 61-66. [Bai FP, Jin RN, Tang S, et al. Research and development of chemical constituents and application of Chinese medicine Agarwood[J]. Chinese Wild Plant Resources, 2022, 41(12): 61-66.] DOI: 10.3969/j.issn.1006-9690.2022.12.012.

9.Hashim YZ, Kerr PG, Abbas P, et al. Aquilaria spp. (agarwood) as source of health beneficial compounds: a review of traditional use, phytochemistry and pharmacology[J]. J Ethnopharmacol, 2016, 189: 331-360. DOI: 10.1016/j.jep.2016.06.055.

10.田燕泽, 秘效媛, 朴香兰. 沉香的化学成分、药理活性与临床应用研究进展[J]. 中央民族大学学报(自然科学版), 2010, 19(1): 77-81. [Tian YZ, Bi XY, Piao XL. Studies on chemical constituents,pharmaceutical effects and clinical application of Aquilaria sinensis[J]. Journal of Minzu University of China (Natural Sciences Edition), 2010, 19(1): 77-81.] DOI: 10.3969/j.issn.1005-8036.2010.01.013.

11.秦宇仙, 徐琳, 余冯萍, 等. 纤维素酶辅助水蒸气蒸馏提取肉豆蔻挥发油的品质及其活性评价[J]. 食品与发酵工业, 2022, 48(10): 112-118. [Qin YX, Xu L, Yu FP, et al. Quality and activity of nutmeg volatile oil extracted by cellulase assisted steam distillation[J]. Food and fermentation industries, 2022, 48(10): 112-118.] DOI: 10.13995/j.cnki.11-1802/ts.029070.

12.刘润润, 孙爱清, 于小钧, 等. 肉豆蔻化学成分和药理作用研究进展及其质量标志物(Q-Marker)预测分析 [J]. 中草药, 2023, 54(14): 4682-4700. [Liu RR, Sun AQ, Yu XJ, et al. Research progress on chemical composition and pharmacological effects of Myristicae semen and predictive analysis on its quality marker[J]. Chinese Traditional and Herbal Drugs, 2023, 54(14): 4682-4700.] DOI: 10.7501/j.issn.0253-2670.2023.14.029.

13.张子英, 伊乐, 爱民, 等. 肉豆蔻挥发油对大鼠心肌的保护作用[J]. 内蒙古中医药, 2013, 32(13): 123-124. DOI: 10.16040/j.cnki.cn15-1101.2013.13.060.

14.马可, 南星梅, 苏姗姗, 等. 肉豆蔻挥发油对低氧诱导肺动脉平滑肌细胞增殖的抑制作用及其抗氧化活性[J]. 中国药理学与毒理学杂志, 2018, 32(7): 535-542. [Ma K, Nan XM, Su SS,et al. Inhibitory effect of volatile oil from Myristica fragrans on hypoxia induced proliferation of pulmonary artery smooth muscle cells and its antioxidant activity[J]. Chinese Journal of Pharmacology and Toxicology, 2018, 32(7): 535-542.] DOI: 10.3867/j.issn.1000-3002.2018.07.004.

15.Seneme EF, Dos Santos DC, de Lima CA, et al. Effects of myristicin in association with chemotherapies on the reversal of the multidrug resistance (MDR) mechanism in cancer[J]. Pharmaceuticals(Basel), 2022, 15(10): 1233. DOI: 10.3390/ph15101233.

16.赵金凤, 周春兰, 周凤琴, 等. 乳香挥发性成分GC-MS分析[J]. 中国中药杂志, 2011, 36(8): 1050-1053. [Zhao JF, Zhou CL, Zhou FQ, et al. GC-MS analysis of volatile oil of olibanum[J]. China Journal of Chinese Materia Medica, 2011, 36(8): 1050-1053.] DOI: 10.4268/cjcmm20110824.

17.夏华玲, 赵新杰. 乳香挥发油化学成分的GC-MS分析 [J]. 中草药, 2003, 34(2): 119. DOI: 10.3321/j.issn:0253-2670. 2003.02.010.

18.谢梦蝶, 王衬衬, 李冰涛, 等. 基于体外细胞实验和网络药理学研究乳香挥发油抗心脏肥大的作用机制 [J]. 中国临床药理学与治疗学, 2022, 27(3): 241-252. [Xie MD, Wang CC, Li BT, et al. Analysis on mechanism of frankincense volatile oil in prevention and treatment of cardiac hypertrophy based on in vitro cell experiment and network pharmacology[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 241-252.] DOI: 10.12092/j.issn.1009-2501.2022.03.001.

19.汪莹, 赵焰焰, 闫凯莉, 等. GC-MS结合网络药理学与分子对接探讨乳香挥发油镇痛的活性成分及作用机制[J]. 世界科学技术-中医药现代化, 2021, 23(11): 4180-4191. [Wang Y, Zhao YY, Yan KL, et al. Active components and mechanism of action of Olibanum volatile oil for analgesia explored by GC-MS combined with network pharmacology and molecular docking[J]. World Science and Technology-Modernization of Traditional Chinese Medicine and Materia Medica, 2021, 23(11): 4180-4191.] DOI: 10.11842/wst.20210119010.

20.叶琪, 苏宏娜, 杨艺, 等. 乳香有效成分治疗冠心病的作用机制研究进展[J]. 中草药, 2023, 54(16): 5379-5389. [Ye Q, Su HN, Yang Y, et al. Research progress on mechanisms of effective components from Olibanum in treatment of coronary heart disease[J]. Chinese Traditional and Herbal Drugs, 2023, 54(16): 5379-5389.] DOI: 10.7501/j.issn.0253-2670.2023.16.027.

21.郑加梅, 尚明越, 王嘉乐, 等. 木香的化学成分、药理作用、临床应用研究进展及质量标志物预测[J]. 中草药, 2022, 53(13): 4198-4213. [Zheng JM, Shang MY, Wang JL, et al. Research progress on chemical constituents, pharmacological effects and clinical applications of Aucklandiae radix and prediction analysis on Q-Marker[J]. Chinese Traditional and Herbal Drugs, 2022, 53(13): 4198-4213.] DOI: 10.7501/j.issn.0253-2670.2022.13.033.

22.侯鹏飞, 陈文星, 赵新慧, 等. 木香挥发性成分气质联用分析及其抑制血小板聚集作用的研究[J]. 中国实验方剂学杂志, 2008, (7): 26-30. [Hou PF, Chen WX, Zhao XH, et al. Analysis of chemical composition of the essential oil from Radix aucklandiae by GC-MS and the effect on platelet aggregation[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2008, (7): 26-30.] DOI: 10.13422/j.cnki.syfjx.2008.07.013.

23.金清. 云木香中降糖活性成分的分离及降糖机制研究 [D].重庆: 西南大学, 2012. DOI: 10.7666/d.y2087047.

24.魏华, 彭勇, 马国需, 等. 木香有效成分及药理作用研究进展[J]. 中草药, 2012, 43(3): 613-620. [Wei H, Peng Y, Ma GX, et al. Advances in studies on active components of Saussurea lappa and their pharmacological actions[J]. Chinese Traditional and Herbal Drugs, 2012, 43(3): 613-620.] DOI: 10.7501/j.issn.0253-2670.

25.吴剑涓, 李文明, 李腾飞. HPLC-DAD法同时测定八味沉香散中的6种成分[J]. 中草药, 2014, 45(24): 3569-3572. [Wu JJ, Li WM, Li TF. Simultaneous determination of six components in Bawei Chenxiang powders by HPLC-DAD[J]. Chinese Traditional and Herbal Drugs, 2014, 45(24): 3569-3572.] DOI: 10.7501/j.issn.0253-2670.2014.24.013.

26.汪莹, 张玉珊, 孙丽平, 等. 乳香炮制后挥发性成分的变化及含量测定[J]. 中国药房, 2022, 33(10): 1172-1176. [Wang Y, Zhang YS, Sun LP, et al. Changes of volatile components and their content determination of Olibanum after processing[J]. China Pharmacy, 2022, 33(10): 1172-1176.] DOI: 10.6039/j.issn.1001-0408.2022.10.04.

27.杨彩静, 曹人郦, 赵颖, 等. 气相色谱法同时测定扎冲十三药材中6种挥发性成分的含量[J]. 中国药房, 2019, 30(12): 1650-1654. [Yang CJ, Cao RL, Zhao Y, et al. Simultaneous determination of the contents of 6 volatile components in Zhachong Shisan by GC[J]. China Pharmacy, 2019, 30(12): 1650-1654.] DOI: 10.6039/j.issn.1001-0408.2019.12.13.

28.王丽丽，饶伟文，周文杰. GC法同时测定枫香精油中4个主要成分的含量[J]. 中国药师, 2022, 25(10): 1836-1840. [Wang LL, Rao WW, Zhou WJ. Simultaneous determination of four components in essential oil of Liquidambaris resin by GC[J]. China Pharmacist, 2022, 25(10): 1836-1840.] DOI: 10.19962/j.cnki.issn1008-049X.2022.10.030.